Positive Results for Phase 2 Trial of Antiobesity Compound

FEBRUARY 01, 2006
Susan Farley

In the treatment of obesity, the compound APD356 manufactured by Arena Pharmaceuticals Inc yielded good results in a recent phase 2 clinical trial. The randomized, double-blind trial took place over 12 weeks and included 469 male and female obese patients. The patients, whose body mass indexes were between 29 and 46, received APD356 in daily doses of 10 mg, 15 mg, 20 mg (bid), or placebo. The compound was associated with statistically significant results when compared with placebo: the average weight loss was 4.0, 5.7, and 7.9 lb at the 10-, 15-, and 20-mg doses of APD356, respectively. The placebo group lost 0.7 lb. Four serious adverse events were associated with the trial, with 2 occurring in the placebo group, and the other 2 were deemed preexisting conditions. More mild adverse effects included headache, nausea, dizziness, and vomiting. Principal investigator Steven Smith, MD, commented: "The results of this trial are extremely encouraging and unambiguously support further study of APD356. This trial demonstrated excellent weight loss, particularly considering there was no diet or exercise component in this trial."

Ms. Farley is a freelance medical writer based in Wakefield, RI.